Compare VTRS & ACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | ACI |
|---|---|---|
| Founded | 1961 | 1860 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | VTRS | ACI |
|---|---|---|
| Price | $10.96 | $17.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $11.17 | ★ $24.14 |
| AVG Volume (30 Days) | 7.9M | ★ 8.6M |
| Earning Date | 11-06-2025 | 01-07-2026 |
| Dividend Yield | ★ 4.39% | 3.48% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.69 |
| Revenue | $14,124,400,000.00 | ★ $81,370,600,000.00 |
| Revenue This Year | N/A | $4.87 |
| Revenue Next Year | $1.16 | $0.53 |
| P/E Ratio | ★ N/A | $10.17 |
| Revenue Growth | N/A | ★ 2.08 |
| 52 Week Low | $6.85 | $16.70 |
| 52 Week High | $13.13 | $23.20 |
| Indicator | VTRS | ACI |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 38.17 |
| Support Level | $10.67 | $17.84 |
| Resistance Level | $10.93 | $18.28 |
| Average True Range (ATR) | 0.24 | 0.39 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 90.23 | 7.54 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.